![]() Jazz currently has a Zacks Rank of #3 (Hold). This represents a change of +8% from what the company reported a year ago. JAZZ has returned 5.8% over the past month.įor Jazz, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $4.21. One other stock in the same industry, Jazz Pharmaceuticals ( JAZZ Quick Quote JAZZ - Free Report), finished the last trading session 1.3% lower at $158.30. is a member of the Zacks Medical - Drugs industry. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here > The stock currently carries a Zacks Rank #1 (Strong Buy). So, make sure to keep an eye on PRPH going forward to see if this recent jump can turn into more strength down the road. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. Revenues are expected to be $18.02 million, up 97.2% from the year-ago quarter.Įarnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.įor ProPhase Labs, Inc., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +288.9%. ProPhase has also formed a new subsidiary to expand its COVID-19 testing into other countries. The company aims to provide these services directly to the consumer and build a genomics data base to be used for further research. The rise in share price is attributable to positive investor expectations for PRPH’s diagnostics and genomics testing services. This compares to the stock's 14.5% gain over the past four weeks. ![]() This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. ( PRPH Quick Quote PRPH - Free Report) shares rallied 9.1% in the last trading session to close at $14.15. It also engages in the research and development of potential over-the-counter drugs.ProPhase Labs, Inc. ![]() ProPhase makes and distributes a range of homeopathic and health products. "We believe ProPhase faces significant challenges by remaining as a standalone entity, including lack of scale, an unsustainable financial model and limited liquidity," Matrixx chief executive Marylou Arnett said. ![]() Matrixx, also a maker of cold and sinus medications, said its revised all-cash offer is not contingent on financing and is "highly attractive to ProPhase shareholders." Shares of ProPhase gained 10 cents to hit $1.45 on the Nasdaq on Tuesday - well below the newest bid price.īased on ProPhase's 14.84 million outstanding common shares, the deal is pegged somewhere around $23.7 million. The revised offer is a 19 per cent premium to ProPhase's Monday closing price of $1.35. Matrixx's new bid of $1.60 per share tops its May offer for the cold remedy company of $1.40 per share. Cold-Eeze maker ProPhase Labs Inc.'s ( NASDAQ:PRPH) stock popped after Matrixx Initiatives raised its takeover offer for the company by 14.3 per cent.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |